Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$210.12 USD

210.12
983,441

+12.55 (6.35%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.

Illumina (ILMN) Progresses in Pathogen Genomic Technologies

by Zacks Equity Research

Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.

Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo

by Zacks Equity Research

Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.

LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays

by Zacks Equity Research

LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.

Here's Why Investors Should Retain Henry Schein (HSIC) for Now

by Zacks Equity Research

Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.

Integra (IART) Builds Advanced R&D Facility in New Jersey

by Zacks Equity Research

Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

by Zacks Equity Research

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays

by Zacks Equity Research

Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.

Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?

by Zacks Equity Research

Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.

Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing

by Zacks Equity Research

Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.

Zacks.com featured highlights include Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk

by Zacks Equity Research

Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk are part of the Zacks Screen of the Week article.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Endure Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.

Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust

by Zacks Equity Research

Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.

Penumbra (PEN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 109.09% and 4.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCG

Penumbra (PEN) Q4 Earnings Top Estimates, Sales Remain Robust

by Zacks Equity Research

Penumbra's (PEN) sales during the fourth quarter reflect continued demand for its products. The 2023 outlook is encouraging as EPS improves despite macro challenges.

Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.

Should You Buy Penumbra (PEN) Ahead of Earnings?

by Zacks Equity Research

Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of February 13, 2023

by Panel Of Zacks Experts

A Medical and Financial Stock Worth a Look.